People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why - There’s no direct link ...

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...

At medical conferences and hospital cafeterias, one thing has become increasingly clear—many doctors are using Ozempic, ...

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

As the first earnings season of 2025 unfolds, investors are likely analyzing financial reports to refine their portfolio strategies.